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Abstract
Amajor component of increased mortality risk in people with chronic kidney disease (CKD)
is associated with non-traditional cardiovascular risk factors including markers of inflamma-
tion. We studied whether a novel marker of systemic inflammation, elevated serum com-
bined polyclonal immunoglobulin free light chains (cFLC), was an independent risk factor
for increased all-cause mortality in people with CKD stage 3. In a prospective community
based cohort study, 1695 participants with stage 3 CKD and no cases of monoclonal gam-
mopathy had cFLC concentrations measured. cFLC levels were determined using the sum-
mation of Freelite kappa and lambda assays. All other bioclinical variables were collected at
the time of sample collection. Kaplan-Meier plots and Cox proportional hazards analysis
was used to assess the relationship between high cFLC levels (>43.3 mg/L) and mortality.
There were 167 deaths (10%) after a median of 1375 days. cFLC levels at recruitment were
higher in participants who died compared with those who were alive at the end of the study;
median: 46.5 mg/L (IQR: 36.1-65.4 mg/L) and 35.4 mg/L (28.1-46.6 mg/L) respectively, P
<0.001. Kaplan-Meier survival analysis demonstrated participants with cFLC >43.3 mg/L
levels had an increased risk of mortality compared to people with normal cFLC levels (P
<0.001). Elevated cFLC levels were independently associated with worse survival (Hazard
ratio: 1.50; 95% confidence interval: 1.04-2.16; P=0.03). Other independent risk factors for
worse survival were: older age, male gender, previous cardiovascular event, lower eGFR
and higher high sensitivity C-reactive protein (hsCRP). To conclude, high cFLC levels pre-
dict increased mortality in people with stage 3 CKD, independent of established risk factors
and other markers of inflammation.
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Introduction
Chronic kidney disease (CKD) is associated with an increased risk of mortality that increases
as glomerular filtration rate (GFR) decreases below 60 ml/min per 1.73m2 [1, 2]. Whilst some
of the increased mortality risk is associated with traditional cardiovascular risk factors, includ-
ing hypertension, diabetes and dyslipidaemia, a major component is attributable to non-
traditional factors [3, 4]. Among these, systemic inflammation is emerging as an important
contributor to the pathogenesis of cardiovascular disease (CVD) associated with CKD. Previ-
ous studies have focused on C-reactive protein (CRP) or cytokines as markers of inflammation
[5, 6] but alternative biomarkers are needed to further improve detection of a subclinical
inflammatory state and facilitate risk prediction in individuals with CKD.
One novel biomarker of systemic inflammation is serum free light chains (FLC). Each cell of
the B-cell lineage produces one of two isotypes of immunoglobulin (Ig) light chain (LC), kappa
(κ) or lambda (λ). The majority of Ig LC produced is incorporated into intact Ig molecules, but
around 500 mg/day is released into the extracellular compartment [7, 8]. At molecular weights
of ~22.5 kDa (κFLC) and ~45 kDa (λFLC), these molecules are predominantly cleared by the
kidneys and therefore accumulate with declining kidney function [9, 10]. In addition, elevated
polyclonal FLC levels occur with global immune activation [11, 12] and may therefore serve as
a marker of systemic inflammation. Moreover, recent studies have shown that elevated com-
bined polyclonal FLC levels (cFLC = κFLC plus λFLC) are associated with increased mortality
in both community based and secondary care non-CKD cohorts [13–15].
We have previously shown a weak independent association between λFLC levels and mor-
tality in a cohort of people with advanced CKD (median eGFR 21.9 ml/min per 1.73m2) and
high vascular comorbidity recruited from secondary care clinics [16] and a stronger association
was seen between cFLC and mortality in a larger secondary care cohort incorporating all non-
dialysis CKD stages [17]. However there has been no assessment of the relationship between
cFLC and mortality in early CKD when the patient would still be under the care of a general
practitioner, and when risk stratification is arguably even more important. Therefore, the pur-
pose of this study was to assess the relationship between cFLC levels and mortality in a cohort
of people with early CKD, predominantly stage 3. Elevated cFLC was independently associated
with poorer overall survival within this population.
Materials and Methods
The Renal Risk in Derby (R2ID) study is a large prospective cohort study to investigate out-
comes in 1741 patients with early CKD under follow-up by a primary care physician. Partici-
pants were recruited directly from 32 community (primary care) medical centres on the basis
of two previous eGFR values of 30–59 ml/min per 1.73m2 at least 3 months apart. Due to intra-
patient variability in the eGFR test, some patients had an eGFR value outside the stage 3 CKD
range at the first study visit. These patients were included in the study because they met the
entry criteria prior to the first study visit. First study sample collections were conducted
between August 2008 to March 2010 and last follow-up was set to 24th February 2014 (Fig 1).
The study collected a detailed bioclinical dataset including serum samples that were aliquoted
and stored at -80°C for future analysis. Detailed methods have been published previously [18–
20]. The cohort is under long-term follow-up for clinical outcomes including mortality.
Forty-six participants (3%) recruited in the complete cohort were not included in this study
as they had evidence of a monoclonal gammopathy as defined by the presence of a monoclonal
band by serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE) (Sebia
Hydragel Immunofixation PE kit on the Hydrasys system) and/or an abnormal FLC ratio, indi-
cating clonal expression of FLC, as determined using the renal reference range (0.37–3.1) [9].
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FLC values obtained in the study population were compared with values previously obtained in
a group of normal volunteers (N = 282, age range: 21–90 years), using the same assay, details of
which have been published previously [21].
The study was approved by the Nottingham Research Ethics Committee 1 and abides by the
principles of the Declaration of Helsinki. All participants provided written consent. The study
was included on the National Institute for Health Research (NIHR) Clinical Research Network
Portfolio (NIHR Study ID: 6632) and was independently audited by QED Clinical Services in
November 2009.
Fig 1. Study flow diagram.
doi:10.1371/journal.pone.0129980.g001
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Outcome data
Participants were registered with the UK Health and Social Care Information Service to obtain
date and cause (as recorded on the death certificate) of all deaths. The cause of death was classi-
fied independently by three clinical investigators as cardiovascular, cancer, infection and other.
Differences in classification were resolved through discussion to reach a consensus.
Laboratory analyses
Samples were analysed for serum κFLC, serum λFLC [22] (Freelite, The Binding Site Group
Ltd, Birmingham, UK) and serum high-sensitivity CRP (hsCRP, Roche Diagnostics, Newha-
ven, UK). Assays were performed using a Roche Modular P Analyser (Roche Diagnostics) and
run in accordance with the manufacturer’s instructions. The normal reference ranges used for
the FLC analyses were: κFLC 3.3–19.4 mg/L, λFLC 5.71–26.3 mg/L [21]. The cFLC concentra-
tion was calculated for each sample by addition of the κFLC and λFLC values. The published
95th percentile normal range for cFLC is 9.3–43.3 mg/L [14].
The creatinine assay has been standardized against an isotope dilution mass spectrometry
(IDMS) method and the 4-variable Modification of Diet in Renal Disease (MDRD) equation
modified for use with IDMS standardized creatinine measurement was used to estimate GFR.
This study was commenced prior to publication of the CKD-EPI formula and eGFR derived
from the MDRD formula was therefore used for recruitment and baseline study assessments.
Clinical outcomes and statistical analysis
Statistical differences between cFLC and other biomarkers on a continuous scale were assessed
using Kruskall-Wallis or MannWhitney U tests. Categorical variables were compared using
Chi-squared analysis. Correlation analyses were performed using Spearman rank analysis.
Univariate and multivariable logistic regression analyses were used to identify the associa-
tions of elevated cFLC (>43.3 mg/L). The multivariable model included variables that were sta-
tistically significant (P<0.05) on univariate analyses (with the exception of total cholesterol/
HDL ratio as cholesterol and HDL were included separately). Variables were also excluded
from the multivariable model where there was no clear clinical rationale for their inclusion
(sodium, potassium and urea).
The cohort was followed prospectively until death or the end of the study period. Patients
who were alive at the end of the study were censored according to their follow up time. A
Kaplan-Meier curve was generated to determine the frequency of death over the period of fol-
low up. Log-rank analysis was used to calculate the significance. Univariate analysis was used
to determine which factors were associated with time to mortality. Univariate comparisons
were made with subsequent addition of variables to the multivariable Cox proportional hazards
model if they were found to have P<0.10 on univariate analysis and were considered clinically
relevant. The order of addition of variables was socio-demographic (age, gender) and then clin-
ical or laboratory (CVD, diabetes, hypertension, smoking, BMI, central obesity, total:HDL
cholesterol ratio, eGFR, uACR, hemoglobin (Hb), platelets, white blood cell count (WBC), cho-
lesterol, HDL, uric acid, diastolic blood pressure (DBP). The primary outcome was all-cause
mortality. Despite meeting the inclusion criteria (and therefore having a clinical diagnosis of
CKD stage 3), some participants were found to have a baseline eGFR60ml/min per 1.73m2.
Sensitivity analyses were therefore conducted in only those whose baseline eGFR was<60ml/
min per 1.73m2 (n = 1283). All statistical analysis was performed using SPSS v19.0 (SPSS Chi-
cago, USA) and Stata v12.0 (StataCorp. 2011. Stata Statistical Software: Release 12. College Sta-
tion, TX: StataCorp LP).
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Results
Population characteristics and biochemical markers
The baseline demographic and laboratory data of the study population are shown in Tables 1
and 2. Subjects were predominantly white (97%) and female (61%), with a median age of 74
years (interquartile range (IQR): 67–79 years). 17% had diabetes and 22% had previous cardio-
vascular event (as defined by a self-reported previous cardiovascular event). The median eGFR
was 53.2 ml/min per 1.73m2 (IQR: 45.6–59.8 ml/min per 1.73m2).
Polyclonal serum free light chains
The median serum κFLC concentration was 19.2 mg/L (IQR: 14.4–25.5 mg/L) and serum
λFLC concentration was 17.3 mg/L (IQR: 13.5–22.7 mg/L) (Table 2); these were significantly
elevated compared to previously reported FLC values in a normal healthy control population
[21, 23] (κFLC median 7.3 mg/L; λFLC median 12.4 mg/L, P<0.001) (Fig 2A and 2B). The
median cFLC concentration for the CKD population was 36.3 mg/L (IQR: 28.6–47.9 mg/L)
(Table 2 and Fig 2C); median κ/λFLC ratio was 1.1 (IQR: 0.9–1.3), which was significantly
higher than controls, P<0.001 (Fig 2D). Males had significantly elevated cFLC concentrations
compared to females: 41.95 mg/L (IQR:32.86–54.78 mg/L) vs 33.31 mg/L (IQR:26.85–44.32
mg/L) respectively P<0.001 (Fig 3). cFLC levels were elevated (>43.3 mg/L) in 584 (34%)
patients. cFLC correlated inversely with eGFR (rho = -0.49, P<0.0001; Fig 4, Table 3). Weak
but significant correlations were observed between cFLC and albumin (rho = -0.28), hsCRP
(rho = 0.19), Hb (rho = -0.22), cholesterol (rho = -0.25), HDL cholesterol (rho = -0.23), PWV
(rho = 0.11), uACR (rho = 0.32), DBP (rho = -0.14) and WHR (rho = 0.27) (P<0.01 for all).
There was no significant correlation between cFLC and BMI, calcium or phosphate levels.
Table 1. Baseline patient demographics and clinical variables in relation to serum cFLC levels.
Variable Whole CKD population cFLC 43.3mg/L N = 1111 cFLC >43.3mg/L N = 584 P value
Age (Years) 74 (67–79) 73 (66–78) 76 (70–81) <0.001
Male (%) Female (%) 39 61 33 67 53 47 <0.001
Ethnicity (%)
White 97 98 95
Asian 1.7 1 3 0.03
African-Caribbean 0.3 0.1 0.7
Other 1 0.9 1.3
Smoker (%) 5 4 6 0.05
Total pack years 0.8 (0–195) 0 (0–195) 5 (0–141) <0.001
Diabetic (%) 17 14 23 <0.001
Previous CVD (%) 22 20 27 0.03
BMI (kg/m2) 28.6 (25.7–31.9) 28.6 (25.7–31.9) 28.5 (25.7–31.8) 0.70
WHR 0.9 (0.8–1.0) 0.9 (0.8–1.0) 0.9 (0.9–1.0) <0.001
PWV (m/s) 9.8 (8.5–11.1) 9.6 (8.5–10.9) 10 (8.7–11.3) 0.01
SBP (mmHg) 133 (122.3–114.0) 133 (122.0–143.0) 134 (122.7–146.3) 0.07
DBP (mmHg) 73.0 (65.0–80.3) 73.7 (66.0–81.3) 70.3 (62.7–79.0) <0.001
Categorical variables analysed using Chi-square test and continuous variables were analysed using independent Mann-Whitney U test. ACR = urinary
albumin/creatinine ratio, BMI = body mass index, cFLC = combined free light chains, CVD = cardiovascular disease, DBP = diastolic blood pressure,
PWV = pulse wave velocity, SBP = systolic blood pressure, WHR = waist hip ratio.
doi:10.1371/journal.pone.0129980.t001
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Participants with elevated cFLC (>43.3 mg/L) were older, had a higher waist to hip ratio
(WHR), elevated pulse wave velocity (PWV), higher urinary albumin to creatinine ratio
(uACR), elevated serum hsCRP and uric acid levels. Elevated cFLC was associated with lower
levels of Hb, reduced albumin, and lower eGFR (Tables 1 and 2).
On univariate logistic regression analysis at baseline, elevated cFLC was associated with age,
gender, diabetes, previous cardiovascular event, hypertension, smoking, eGFR, uACR, hsCRP,
PWV, serum albumin, Hb, WBC, total protein, bicarbonate, cholesterol, HDL, and uric acid.
The associations with age, gender, smoking, eGFR, uACR, serum albumin, Hb, total protein,
cholesterol and HDL cholesterol were maintained after full adjustment (Table 4).
Survival analysis
At analysis, the median duration of patient follow-up was 1375 days (1152–1502). There were
167/1695 deaths from all causes (10%). Of the total deaths, 102 patients (61%) had elevated
cFLC. The most frequent primary causes of death were CVD (42%), infections (29%), cancer
(21%) and death due to other causes (8%). The median cFLC concentration at recruitment was
significantly higher in participants who died compared with those who were alive at the end of
the observation period; 46.5 mg/L (IQR: 36.1–65.4 mg/L) vs 35.4 mg/L (IQR: 28.1–46.6 mg/L),
P<0.001. Kaplan-Meier survival analysis demonstrated that patients with a cFLC level in the
Table 2. Baseline patient characteristics in relation to serum cFLC levels.
Variable Whole CKD population cFLC 43.3mg/L N = 1111 cFLC >43.3mg/L N = 584 P value
Urea (mmol/L) 8 (6.6–9.9) 7.4 (6.3–8.7) 9.5 (7.8–11.5) <0.001
eGFR (ml/min per 1.73m2) 53.2 (45.6–59.8) 56.0 (49.6–61.7) 46.2 (39.2–53.7) <0.001
Albumin (g/L) 41 (39–43) 41 (39–43) 40 (38–42) <0.001
Potassium (mmol/L) 4.4 (4.1–4.7) 4.3 (4.1–4.6) 4.5 (4.2–4.8) <0.001
Sodium (mmol/L) 140 (138–141) 140 (138–142) 139 (138–141) <0.001
Bicarbonate (mmol/L) 26 (24–27) 26 (24–27) 25 (23–27) <0.001
Total Protein (g/L) 74 (71–77) 74 (71–77) 75 (71–78) <0.001
Cholesterol (mmol/L) 4.6 (3.9–5.5) 4.8 (4.1–5.7) 4.3 (3.6–5.1) <0.001
HDL (mmol/L) 1.4 (1.1–1.7) 1.5 (1.2–1.8) 1.3 (1–1.6) <0.001
Uric acid (μmol/L) 379 (320–441) 360 (307–418) 415 (355–481) <0.001
Hb (g/L) 133 (123–141) 134 (125–143) 128 (119–138) <0.001
Correted calcium (mmol/L) 2.4 (2.3–2.4) 2.4 (2.3–2.4) 2.4 (2.3–2.4) 0.78
Phosphate (mmol/L) 1.1 (1–1.2) 1.1 (1–1.2) 1.1 (1–1.2) 0.18
hsCRP (mg/L) 2.23 (1.14–4.62) 2.02 (1.1–3.9) 2.97 (1.4–5.6) <0.001
ACR (mg/mmol) 0.3 (0–1.5) 0.2 (0–0.8) 1.0 (0.1–4.1) <0.001
Platelet count (x103/μL) 239 (202–284) 239 (206–284) 237 (197–284) 0.59
WBC (x103/μL) 6.9 (5.8–8.1) 6.7 (5.8–8.0) 7.1 (6.0–8.3) <0.001
Serum κFLC (mg/L) 19.2 (14.4–25.5) NA NA NA
Serum λFLC (mg/L) 17.3 (13.5–22.7) NA NA NA
κ/λ ratio 1.1 (0.9–1.3) NA NA NA
cFLC (mg/L) 36.3 (28.6–47.9) NA NA NA
Categorical variables analysed using Chi-square test and continuous variables were analysed using independent Mann-Whitney U test. NA = not
applicable, ACR = urinary albumin/creatinine ratio cFLC = combined free light chains, eGFR = estimated glomerular ﬁltration rate (calculated using the
Modiﬁcation of Diet in Renal Disease (MDRD) equation), FLC = free light chains, Hb = hemoglobin, κ = kappa, HDL = high density lipoprotein,
hsCRP = high sensitivity C-reactive protein, λ = lambda, WBC = white blood cell count.
doi:10.1371/journal.pone.0129980.t002
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normal range (43.3 mg/L) had better overall survival than those with cFLC>43.3 mg/L (log-
rank analysis, P<0.001) (Fig 5).
Univariate Cox proportional hazards analysis identified a number of factors that were sig-
nificantly associated with higher all-cause mortality (Table 5). Multivariable analyses showed
that elevated cFLC concentration was an independent predictor of all-cause mortality in addi-
tion to older age, gender, previous cardiovascular event, lower eGFR and higher hsCRP con-
centrations (Table 5). Sensitivity analysis including only patients with eGFR<60ml/min per
1.73m2 at baseline gave similar results although there was no longer an association with eGFR
on multivariable analysis (HR: 0.99; 95% CI: 0.97–1.02); all other associations remained.
Discussion
Previous studies have reported an association between elevated FLC and increased risk of mor-
tality in 2 independent cohorts of patients with advanced CKD attending specialist nephrology
clinics in secondary care. Here, we have identified serum cFLC levels as an independent predic-
tor of reduced survival in a large cohort of people with relatively early stage CKD, most of
whom had never been referred to a nephrologist. Furthermore, this study represents the largest
Fig 2. Serum FLC concentration in people with stage 3 chronic kidney disease versus normal controls. A) κfree light chains (FLC), B) λFLC and C)
Combined free light chains (cFLC) levels were elevated in people with chronic kidney disease (CKD) (circles) versus published normal control individuals
[21]. D) The FLC κ/λ ratio was also significantly higher in people with CKD compared to the healthy control population. Median and ranges are indicated
(black bars).
doi:10.1371/journal.pone.0129980.g002
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cohort of people with a known chronic disease that have been assessed for cFLC levels and
mortality. Our observations therefore support the hypothesis that systemic inflammation is an
important contributor to CVD and excess mortality in CKD. Moreover, our finding that cFLC
was a predictor of reduced survival independent of hsCRP, suggests that cFLC is a more sensi-
tive biomarker of systemic inflammation that adds prognostic information to hsCRP alone.
We focused on stage 3 CKD because it includes the majority of patients with known CKD and
is a heterogeneous group with variable prognosis in who improved risk stratification would be
clinically useful. We chose survival as the primary outcome for this analysis because the major
risk to these patients is decreased survival primarily due to CVD, rather than progression to
Fig 3. cFLC concentrations in males and females. cFLC concentrations were compared and were
elevated in males compared to females (P<0.001). Median and interquartile ranges are indicated.
doi:10.1371/journal.pone.0129980.g003
Fig 4. Correlation of cFLC and eGFR. There was a significant inverse association with cFLC (combined
serum free light chains) and estimated glomerular filtration rate (eGFR) (rho = -0.49, P <0.0001). Spearman
rank correlation was performed.
doi:10.1371/journal.pone.0129980.g004
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end-stage kidney disease [24]. The prognostic value of cFLC is particularly important in this
context because cardiovascular risk prediction tools developed for the general population do
not take account of non-traditional risk factors and tend to underestimate risk in people with
CKD [25]. Whilst the risk of adverse outcomes in the CKD 3 population is less than those
patients with advanced disease, risk assessment of these patients remains of key importance.
The CKD 3 population make up the majority of patients diagnosed with CKD, however many
of these patients remain under the care of their general practitioner rather than a specialist
nephrology team. Nevertheless, these patients have an increased risk of mortality (165%
increased compared to a non-CKD population), hospitalisation due to cardiovascular compli-
cations (46% increased) and infection (42% increased) [26]. Therefore it is arguably more
important to improve the stratification of these patients for risk of adverse outcomes so that
their management can be adjusted accordingly.
We defined high cFLC concentrations as serum levels above the upper limit of the normal
range in a healthy population [14]. We found that these levels were associated with an increased
risk of death as assessed by Kaplan-Meier analysis and that cFLC remained independently asso-
ciated with an increased risk of death by multivariate Cox proportional hazards analysis. Other
independent variables associated with death included age, gender, eGFR, previous cardiovascu-
lar event and raised hsCRP. Thus, cFLC was a predictor of reduced survival independent of pre-
viously identified predictors.
A previous study that assayed for monoclonal proteins (including monoclonal FLC) and
polyclonal FLC in patients with advanced CKD and high cardiovascular comorbidity showed a
weak independent association between increasing λFLC levels and CKD-related outcomes; the
study was conducted in a smaller secondary care population with advanced CKD (median
Table 3. Correlation of cFLC with other clinical markers.
Correlation of cFLC with: Spearman rho P value
Age 0.25 <0.001
Serum albumin -0.28 <0.001
eGFR -0.49 <0.001
hsCRP 0.19 <0.001
Haemoglobin -0.22 <0.001
Cholesterol -0.25 <0.001
HDL -0.23 <0.001
Uric acid 0.32 <0.001
PWV 0.11 <0.001
ACR 0.32 <0.001
DBP -0.14 <0.001
SBP 0.05 0.03
BMI -0.03 0.20
WHR 0.27 <0.001
Calcium -0.14 0.562
Phosphate 0.016 0.525
Correlation analyses (Spearman rho) were performed between cFLC and other clinical and laboratory
markers in CKD. ACR = urinary albumin/creatinine ratio, BMI = body mass index, DBP = diastolic blood
pressure, eGFR = estimated glomerular ﬁltration rate, HDL = high density lipoprotein, hsCRP = high
sensitivity C- reactive protein, PWV = pulse wave velocity, SBP = systolic blood pressure, WHR = waist hip
ratio.
doi:10.1371/journal.pone.0129980.t003
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eGFR 21.9 ml/min per 1.73m2) and a high prevalence of pre-existing CVD [16]. Markers of
cardiac injury were also included in this study and these independently associated with mor-
tality [16]. A recent study of 848 patients recruited from nephrology clinics with all stages of
non-dialysis CKD (median eGFR 45 ml/min per 1.73m2; median urine ACR 10 mg/mmol)
showed a stronger association when cardiac biomarkers were not included [17]. For compari-
son, the median eGFR in our primary care population was 53 ml/min per 1.73m2and median
urine ACR was 0.3 mg/mmol. Our data therefore confirm and extend these observations by
showing that serum cFLC concentration is a risk factor for reduced survival also in the early
stages of CKD.
The rationale for using cFLC to aid stratification of CKD is twofold. Firstly, FLC represent a
sensitive marker of kidney function, with an exponential relationship between their serum lev-
els and eGFR [9]. This reflects the renal clearance of the molecules; individuals with normal
Table 4. Associations of elevated cFLC (>43.3 mg/L): univariate andmultivariable logistic regression analyses.
Variable Categories Univariate OR (95%
CI)
P
value
Final multivariable model* OR (95%
CI)
P
value
Age (Years) - 1.05 (1.03–1.06) <0.001 1.03 (1.01–1.05) 0.004
Gender (vs female) Male 2.43 (1.97–2.98) <0.001 1.88 (1.37–2.58) <0.001
Diabetes (vs no diabetes) People with diabetes 1.82 (1.40–2.35) <0.001 0.88 (0.62–1.25) 0.49
CVD (vs no CVD) People with CVD 1.50 (1.22–1.85) <0.001 0.86 (0.64–1.14) 0.28
Hypertension (vs no hypertension) People with hypertension 3.80 (2.04–7.09) <0.001 1.11 (0.70–1.75) 0.67
Smoking (vs never smokers) Current smoker 1.73 (1.08–2.78) <0.001 2.13 (1.10–4.12) 0.03
Ex-smoker 1.74 (1.41–2.15) 1.31 (0.99–1.72)
eGFR (ml/min per 1.73m2) 0.91 (0.89–0.92) <0.001 0.93 (0.91–0.94) <0.001
ACR# 1.49 (1.39–1.61) <0.001 1.28 (1.17–1.40) <0.001
High sensitivity CRP# (mg/L) 2.08 (1.68–2.59) <0.001 0.91 (0.67–1.24) 0.56
PWV (m/s) 1.09 (1.04–1.15) 0.001 0.95 (0.88–1.02) 0.14
Serum albumin (g/L) 0.86 (0.83–0.89) <0.001 0.77 (0.73–0.81) <0.001
Hb (g/dL) 0.74 (0.69–0.80) <0.001 0.80 (0.72–0.88) <0.001
WBC (x109) 1.07 (1.02–1.13) 0.009 0.95 (0.89–1.02) 0.14
Total protein (g/L) 1.07 (1.04–1.09) <0.001 1.20 (1.16–1.24) <0.001
Bicarbonate (mmol/L) 0.91 (0.88–0.95) <0.001 0.95 (0.91–1.00) 0.05
Cholesterol (mmol/L) 0.71 (0.64–0.78) <0.001 0.77 (0.67–0.88) <0.001
HDL Cholesterol (mmol/L) 0.34 (0.26–0.44) <0.001 0.63 (0.44–0.89) 0.009
Uric acid (μmol/L) 1.01 (1.01–1.01) <0.001 1.00 (1.00–1.00) 0.06
Total:HDL cholesterol ratio 1.09 (1.00–1.18) 0.05 - -
Central obesity (vs not centrally
obese)
People with central
obesity
1.16 (0.87–1.54) 0.32 - -
BMI (kg/m2) 1.00 (0.98–1.02) 0.63 - -
Platelet count (x109) 1.00 (1.00–1.00) 0.64 - -
Corrected calcium (mmol/L) 0.85 (0.31–2.34) 0.76 - -
Phosphate (mmol/L) 1.61 (0.92–2.85) 0.10 - -
All variables are continuous except for gender, diabetes, previous cardiovascular event, hypertension, smoking status and central obesity.
#Log transformed variable.
*Adjusted for age, gender, diabetes, cardiovascular disease, hypertension, smoking, eGFR, uACR, hsCRP, pulse wave velocity, serum albumin, Hb,
WBC, total protein, bicarbonate, cholesterol, HDL, and uric acid. OR = Odds ratio, 95% CI = 95% conﬁdence interval. ACR = albumin/creatinine ratio,
BMI = body mass index, CVD = cardiovascular disease, cFLC = combined free light chains, HDL = high density lipoprotein, hsCRP = high sensitivity C-
reactive protein,, WBC = white blood cell count. Signiﬁcant variables are highlighted in bold.
doi:10.1371/journal.pone.0129980.t004
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kidney function typically clear κFLC in 2–4 hours at approximately 40% of the glomerular fil-
tration rate and λFLC are cleared inbetween 3–6 hours at 20% of the glomerular filtration rate
[27]. The secondary route of clearance for FLC is through the reticulo-endothelial system
(RES). With end stage kidney disease and dominant clearance by the RES, the half-life of FLC
extends from 2–6 hours to several days [8].
Secondly, polyclonal FLC represent a dynamic marker of the adaptive immune system [11,
28] as the clearance of the molecules is far more rapid than intact immunoglobulins; IgG has a
half-life of around 21 days, IgA and IgM have half-lives of approximately 5–6 days [29, 30].
There are now several publications which describe the relationship between cFLC levels and
disease activity in inflammatory diseases [11, 31–33], infections [15, 34, 35] and malignancies
[36]. Moreover, inflammation is increasingly recognized as an important factor in the patho-
genesis of CVD, with or without CKD. Recently, two studies have reported a relationship
between elevated cFLC levels and mortality in general populations. Dispenzieri and colleagues
showed that for each higher decile of cFLC, there was an increased risk of mortality in over
15,000 people from Olmsted County [14]. Similarly, in a study of individuals who had FLC
measured to screen for a monoclonal disease but had no evidence of monoclonality, elevated
cFLC was an independent risk factor for death [13]. Interestingly in our study, higher cFLC
concentration was associated with reduced survival independent of hsCRP, suggesting that
cFLC may be a more sensitive biomarker of systemic inflammation that adds prognostic infor-
mation to hsCRP alone.
Whether elevated cFLC levels are just a marker of poor outcome or have a pathogenic role
in disease is uncertain. There is evidence that cFLC can inhibit the phagocytic activity of leuko-
cytes [37] and in autoimmune diseases activate mast cells [38]. However, there are no definitive
Fig 5. Kaplan-Meier plot of survival in people with elevated (>43.3mg/L) versus normal combined
serum cFLC concentration. Participants with combined free light chains (cFLC)43.3 mg/L had
significantly longer overall survival compared to participants with cFLC >43.3 mg/L. Log rank analysis: P
<0.001. Note that the x axis does not intersect the y axis at zero.
doi:10.1371/journal.pone.0129980.g005
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mechanisms as yet for these effects and further work is ongoing to elucidate mechanisms
whereby cFLC could contribute to cellular dysfunction in a range of settings.
Our study has several limitations. Although the cohort is broadly representative of people
with CKD being managed in primary care in England [39], the study population was predomi-
nantly white and elderly. Our findings may therefore not be applicable to populations with a
more diverse ethnic composition or in younger patients. Further research in other populations
is required to confirm our findings. Second, further research with longer follow-up and more
outcome events is required to identify whether serum cFLC adds significantly to the power of
Table 5. Univariate andmultivariable Cox proportional hazards analyses showing determinants of all-causemortality.
Variable Categories Univariate HR (95%
CI)
P
value
Final multivariable model* HR
(95% CI)
P
value
Age - 1.10 (1.07–1.12) <0.001 1.07(1.05–1.10) <0.001
Gender (vs female) Male 2.03 (1.50–2.76) <0.001 1.44 (1.02–2.03) 0.04
Diabetes (vs no diabetes) People with diabetes 1.52 (1.06–2.17) 0.02 1.21 (0.82–1.78) 0.33
CVD (vs no CVD) People with CVD 3.28 (2.40–4.47) <0.001 2.33 (1.68–3.23) <0.001
Hypertension (vs no hypertension) People with hypertension 1.27 (0.77–2.09) 0.36 0.83 (0.48–1.44) 0.51
Smoking (vs never smokers) Current smoker 1.59 (0.79–3.21) 0.004 1.99 (0.96–4.12) 0.16
Ex-smoker 1.73 (1.25–2.40) 1.03 (0.72–1.46)
eGFR (ml/min per 1.73m2) 0.94 (0.93–0.96) 0.06 0.98 (0.96–0.99) 0.003
uACR# (mg/mmol) 1.00 (1.00–1.01) 0.34 1.06 (0.94–1.19) 0.33
High sensitivity CRP# (mg/L) 2.55 (1.90–3.41) <0.001 1.83 (1.32–2.52) <0.001
Central obesity (vs not centrally obese) People with central
obesity
0.91 (0.60–1.37) 0.64 0.84 (0.55–1.28) 0.42
PWV (m/s) 1.14 (1.06–1.23) <0.001 0.98 (0.90–1.07) 0.66
Serum albumin (g/L) 0.90 (0.87–0.93) <0.001 0.96 (0.91–1.01) 0.11
cFLC (mg/L) (Categorical vs cFLC
43.3 mg/L)
People with cFLC >43.3
mg/L
3.20 (2.34–4.36) <0.001 1.50 (1.04–2.16) 0.03
BMI (kg/m2) 0.97 (0.94–1.00) 0.06 - -
Total:HDL cholesterol ratio 1.00 (0.89–1.14) 0.94 - -
Hb (g/dL) 0.81 (0.73–0.90) <0.001 - -
Platelet count (x109) 0.99 (0.99–1.00) 0.003 - -
WBC (x109) 1.10 (1.05–1.16) <0.001 - -
Potassium (mmol/L) 1.55 (1.12–2.13) 0.008 - -
Sodium (mmol/L) 1.03 (0.98–1.09) 0.3 - -
Urea (mmol/L) 1.12 (1.09–1.15) <0.001 - -
Corrected calcium (mmol/L) 0.3 (0.06–1.47) 0.14 - -
Phosphate (mmol/L) 0.89 (0.37–2.11) 0.79 - -
Total protein (g/L) 1.00 (0.97–1.03) 0.92 - -
Bicarbonate (mmol/L) 1.01 (0.96–1.08) 0.63 - -
Cholesterol (mmol/L) 0.74 (0.64–0.86) <0.001 - -
HDL (mmol/L) 0.59 (0.40–0.86) 0.007 - -
Uric acid (μmol/L) 1.00 (1.00–1.01) <0.001 - -
All variables are continuous except for gender, diabetes, previous cardiovascular event, hypertension, smoking status and central obesity.
#Log transformed variable.
*Adjusted for age, gender, CVD, diabetes, hypertension, smoking, eGFR, albuminuria, hsCRP, central obesity, PWV, serum albumin. ACR = urinary
albumin/creatinine ratio BMI = body mass index, cFLC = combined free light chains, CVD = cardiovascular disease, hsCRP = high sensitivity C-reactive
protein, DBP = diastolic blood pressure, Hb = hemoglobin, HDL = high density lipoprotein, PWV = pulse wave velocity, SBP = systolic blood pressure,,
WBC = white blood cell count, WHR = waist hip ratio. Signiﬁcant variables are highlighted in bold.
doi:10.1371/journal.pone.0129980.t005
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previously described risk factors such as eGFR and albuminuria to predict survival in people
with CKD.
In conclusion, the relationship observed between elevated polyclonal cFLC levels and subse-
quent mortality risk in a population with early CKD adds further evidence to a role for cFLC as
an independent risk marker. This may have particular relevance in the setting of CKD because
risk prediction tools developed for the general population do not take account of non-tradi-
tional risk factors and tend to underestimate risk in people with CKD. One advantage of using
cFLC as a biomarker is that, unlike many others, the assay for FLC is already widely available
in routine clinical laboratories and clinicians are familiar with it as a common test to screen for
monoclonal gammopathies. Further work is now required to determine if the prospective mea-
surement of cFLC in CKD can be used to improve risk stratification in people with CKD and
direct interventions to those at highest risk while sparing those at low risk from unnecessary
treatment.
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